Argon Laser Photocoagulation for the Treatment of Diabetic Macular Oedema

1992 ◽  
Vol 205 (1) ◽  
pp. 15-18 ◽  
Author(s):  
Milan Ivanišević ◽  
Miladin Štriga ◽  
Rikard Stanić
Eye ◽  
2006 ◽  
Vol 20 (12) ◽  
pp. 1471-1472
Author(s):  
N E Sinclair ◽  
A Booth ◽  
A Clover ◽  
R Newsom

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
O’Sam Shibeeb ◽  
Anagha Vaze ◽  
Mark Gillies ◽  
Timothy Gray

We report a patient with macular oedema due to type 1 macular telangiectasia responding to intravitreal aflibercept injection. A 51-year-old man was diagnosed with type 1 idiopathic macular telangiectasia (IMT) in the right eye. The macular oedema was refractory to initial treatment with intravitreal bevacizumab and argon laser photocoagulation. The patient was then treated with intravitreal aflibercept injections, following which the macular oedema was completely resolved and his vision was significantly improved. Intravitreal aflibercept injection appears to improve vision and reduce persistent macular oedema secondary to type 1 IMT and demonstrated promising anatomical and visual outcomes.


2021 ◽  
pp. bjophthalmol-2020-318690
Author(s):  
Kun Liu ◽  
Hanying Wang ◽  
Wei He ◽  
Jian Ye ◽  
Yanping Song ◽  
...  

BackgroundTo demonstrate the efficacy and safety of intravitreal injections of conbercept versus laser photocoagulation in the treatment of diabetic macular oedema (DME).MethodsA 12-month multicentre, randomised, double-masked, double-sham, parallel controlled, phase III trial (Sailing Study), followed by a 12-month open-label extension study. Patients with centre-involved DME were randomly assigned to receive either laser photocoagulation followed by pro re nata (PRN) sham intravitreal injections (laser/sham) or sham laser photocoagulation followed by PRN 0.5 mg conbercept intravitreal injections (sham/conbercept). Patients who entered the extension study received PRN conbercept treatment. The primary endpoint was the changes in best-corrected visual acuity (BCVA) from baseline.ResultsA total of 248 eyes were included in the full analysis set and 157 eyes continued in the extension study. Significant improvement in mean change in BCVA from baseline to month 12 was observed in the sham/conbercept group (8.2±9.5 letters), whereas no improvement was observed in the laser/sham group (0.3±12.0 letters). Patients in the laser/sham group showed a marked improvement in BCVA after the switch to conbercept in the extension study, and there was no difference in BCVA between the two groups at the end of the extension study.ConclusionThe use of a conbercept PRN intravitreal injection regimen improved the BCVA of patients with DME, and its efficacy was better than that of laser photocoagulations, and the same efficacy was observed when the eyes treated with laser alone were switched to conbercept.Trial registration numberNCT02194634.


2014 ◽  
Vol 107 (2) ◽  
pp. 132
Author(s):  
MohamedY Farag ◽  
DikranG Hovaghimian ◽  
AhmadI Abdulla ◽  
MostafaA El Husseiny

Eye ◽  
1994 ◽  
Vol 8 (4) ◽  
pp. 419-422 ◽  
Author(s):  
Ayala Pollack ◽  
Asher Milstein ◽  
Moshe Oliver ◽  
Miriam Zalish

Sign in / Sign up

Export Citation Format

Share Document